Trials / Completed
CompletedNCT05110118
Pharmacokinetic Characteristics, Safety, Tolerability and Immunogenicity of LY01008 and Avastin in Healthy Chinese Male Subjects
A Randomized, Double-blind, Single-dose, Parallel-group Study Comparing Pharmacokinetic Characteristics, Safety , Tolerability and Immunogenicity of LY01008 (Recombinant Humanized Anti-Human Vascular Endothelial Growth Factor Monoclonal Antibody Injection) and Avastin (Bevacizumab Injection) in Healthy Chinese Male Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 112 (actual)
- Sponsor
- Shandong Boan Biotechnology Co., Ltd · Industry
- Sex
- Male
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
This is a randomized, double-blind, single-dose, parallel-group study comparing pharmacokinetic characteristics, safety , tolerability and immunogenicity of LY01008 (Recombinant Humanized Anti-Human Vascular Endothelial Growth Factor Monoclonal Antibody Injection) and Avastin (Bevacizumab Injection) in healthy Chinese male subjects.
Conditions
- Metastatic Colorectal Cancer
- Non Small Cell Lung Cancer Metastatic
- Non Small Cell Lung Cancer Recurrent
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY01008 | Single intravenous injection |
| DRUG | Avastin | Single intravenous injection |
Timeline
- Start date
- 2020-08-04
- Primary completion
- 2021-01-13
- Completion
- 2021-01-13
- First posted
- 2021-11-05
- Last updated
- 2021-11-05
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05110118. Inclusion in this directory is not an endorsement.